Renal Cell Carcinoma

Two studies suggest no harm from deferred cytoreduction, potential benefits of immunotherapy

ORR of 30% in patients with CD70-positive disease using off-the-shelf, allogeneic product

Duration of response reaches 18.6 months with belzutifan plus cabozantinib

ZIRCON trial meets sensitivity and specificity targets

Over 50% of patients with advanced MET-driven tumors responded to savolitinib plus durvalumab

Updated trial data show nivolumab/cabozantinib doublet "is getting better with age"

News, features, and commentary about cancer-related issues

Approach in small ongoing trial resulted in reduction in tumor size and complexity

CTX130 yields sustained complete response in one patient with relapsed/refractory disease

Thirteen-month survival gain falls short of statistical significance in observational study

Numerical advantage in median survival, response rate, durability with dendritic-cell agent

Nivolumab/ipilimumab achieves 1-year PFS of 100% in unresectable T1N0M0 tumors

Dramatic slowing of disease progression, prolonged responses with microbiome modulator

Randomized study shows "clinically meaningful" PFS improvement over dual immunotherapy alone